Profile data is unavailable for this security.
About the company
Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Bayer and Syngenta in Agriculture and DSM and Adisseo in Animal Health & Nutrition..
- Revenue in DKK (TTM)17.90bn
- Net income in DKK3.02bn
- Incorporated2000
- Employees6.40k
- LocationNovozymes A/SKrogshoejvej 36BAGSVAERD 2880DenmarkDNK
- Phone+45 44460000
- Fax+45 44469999
- Websitehttps://www.novozymes.com/
More ▼
14.70%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 05 Apr 2024 | 12.38m | 2.99% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 8.85m | 2.13% |
| APG Asset Management NVas of 31 Dec 2022 | 7.67m | 1.85% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 5.99m | 1.45% |
| Impax Asset Management Ltd.as of 28 Mar 2024 | 5.31m | 1.28% |
| GuardCap Asset Management Ltd.as of 31 Mar 2024 | 5.23m | 1.26% |
| Handelsbanken Fonder ABas of 31 Mar 2024 | 4.24m | 1.02% |
| MFS International (UK) Ltd.as of 31 Mar 2024 | 4.07m | 0.98% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 3.92m | 0.95% |
| Amundi Asset Management SA (Investment Management)as of 03 Apr 2024 | 3.27m | 0.79% |
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
